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Prevention of cervical cancer in Balkan region 
and in Finland in the HPV era: An introduction 
to brief reports from representatives of different 
countries 
Špela Smrkolj, Urška Ivanuš 
Dear participants of the 4th Regional Symposium on Prevention of Cervical 
Cancer, 
We are glad that the tradition of regional meetings of experts working hard 
for cervical cancer prevention in our region continues and that the 4th meet-
ing will take place in the beautiful Brdo Estate in Slovenia. Slovenian Socie-
ty for Gynaecologic Oncology, Colposcopy and Cervical Pathology and 
National Cervical Cancer Screening Programme ZORA work hand in hand 
to fight this deadly yet almost completely preventable disease in Slovenia. 
We believe that working together is the key to success and the only way to 
reach the World Health Organisation’s 2030 goals toward elimination of 
cervical cancer as the public health problem which are that 90% of girls fully 
are vaccinated against HPV by 15 years of age, 70% of women screened for 
cancer screening in a high quality programme at least at 35 and 45 years of 
age and that 90% of women with identified cervical disease receive treat-
ment.  
In the mid November days in 2019 we will exchange knowledge and experi-
ence in the field of cervical cancer prevention in the region and we will learn 
from each other. Successful cervical cancer prevention needs a good organi-
sation and management, but also enthusiastic professionals with the good 
insight in the current evidence that are willing to push things forward in the 
evidence based way and adapted to local context, even when it seems that 
nothing can be done. 
Dear colleagues gynaecologists, pathologists and epidemiologists from Croa-
tia, Bosnia and Herzegovina, Serbia, Monte Negro, North Macedonia and 
Slovenia we come from different countries and different specialisations. But 
we do share a common history and common goal of the elimination of cer-
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vical cancer in our region. And we all believe it can be done easier, if we will 
continue to work together! 
We wish that the symposium will meet you expectations and that we will all 
go home with new ideas and boosted motivation how to approach the situa-
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Prevention of cervical cancer in Croatia 
Dražan Butorac 
What is the incidence of cervical cancer in the country? 
Crude incidence rate 2018. 12,3; 2018. 266 new cervical cancer cases 
How is cervical cancer screening program organized? Does it fulfil 
criteria for the organised population-based programme? 
An opportunistic screening program based on the Pap test has been used in 
Croatia since 1953. 
In this moment we are prepearing a new organized screening program based 
on the combination of pap smear and hpv tests depending on age groups. 
What are the age range of the target population and the frequency 
of screening?  
There are three groups: 20-29 years, 30-34 years, and 35-64 years 
• First - group Pap test, 
• second co test Pap HPV, 
• and third group HPV test 
What test is used in the primary screening? Do they use liquid-
based technology?  
Pap test, HPV test, and co test. 
We will not use liquid-based tecnology in program 
How is the invitation system organised? What is the coverage of 
the target population with invitations? What is the coverage of the 
target population with screening tests?  
We will see 
 ___________________________     ___________________________  8 
HPV test used in the country and how is it used?  
HPV for women in third age group 35-64 years , and cotest with Pap in 
second groups 
How is vaccination against HPV organised? What is vaccination 
coverage? Do you vaccinate girls and boys 
In 2019, the target group for vaccinations are girls and boys, eighth grade 
students. Due to more vaccines are recommended for high school girls and 
boys. Depending on the county, the response to the vaccination is 2-80%. 
On average 15% 
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Prevention of cervical cancer in Serbia 
Aljoša Mandić 
Oncology Institute of Vojvodina, Serbia 
Cervical cancer is still one of the main problems in female population in 
Serbia. The incidence of cervical cancer in Serbia is among the highest one 
in the Europe. According to our National Register, cervical cancer is on 
forth places among female cancers in Central Serbia but also in Vojvodina, 
North part of Serbia, with incidence rate 20-23/100.000. Graph 1. and 2 
 
Graph 1: Linear-trend of incidence and mortality rate in Vojvodina 
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Graph 2. Comparison of age-specific cervical cancer incidence and mortality 
rates in Serbia (estimates for 2018)- ref.4 
About 1,327 new cervical cancer cases are diagnosed annually in Serbia and 
the 2nd most common female cancer in women aged 15 to 44 years in Ser-
bia. 
About 551 cervical cancer deaths occur annually in Serbia. Cervical cancer 
ranks as the 6th leading cause of female cancer deaths in Serbia and the 2nd 
leading cause of cancer deaths in women aged 15 to 44 years in Serbia. 
Despite the promotion of the cervical screening program, still we have op-
portunistic one, and small number of community-health center is covered 
with full capacities to organized such a program in their communities. The 
cervical cancer screening program is based on conventional PAP smear and 
the cornerstone for implementation of the program are the communities-
health centers with their gynecologists and cytoscreeners.  
According to our national screening program the target population that have 
to be screened are about 2.100.000 women, age 25 to 64, every three years. 
Co-testing with HPV test is not calculated but, HPV testing can be per-
formed in triage in ASCUS, PAP smears. So, HPV testing is recommended 
in our National guidelines for prevention, detection and treatment of cervi-
cal cancer, mostly as triage test. 
The coverage of the target population is about 35-40%,. According to 
screening program, target population will be called by post with brochure 
about importance of screening, schedule time for visiting the gynecologist 
with telephon number of community health center. Plan is to cover 700.000 
in one year with our goal to cover about 75% of the target population 
 ___________________________     ___________________________  11 
(550.000). In Serbia 15 Central laboratory are organized for screening pro-
gram and according to standards we need 4-5 cytoscreeners with full time 
job and one supervisor in each center. 
The primary prevention program for eradication of cervical cancer by im-
plementation of HPV vaccination is still at the beginning and still we do not 
have plan for implementation. The HPV vaccination is in National vaccina-
tion calendar as recommended one, but we still do not have plan how to 
implement organizing vaccination program. The Quadrivalent and Bivalent 
HPV vaccines are registred in Serbia but the Health Insurance Fund does 
not cover them; they are quite expensive for ordinary citizens, and not easily 
obtained in clinics and pharmacies. In study Mitrovic J et al. quantitative 
research was conducted through the internet in December of 2016, using 
the survey method. Participants in the study were parents whose children 
were candidates for the vaccination. The research has shown that nearly one 
third of respondents do not know what HPV is, and about the same number 
of respondents know that HPV causes cancer. With adequate awareness of 
safety, 97% of respondents would decide to vaccinate their children but the 
main problem according to results was cost of vaccinae and only 39% of 
parents could afford the vaccination. Consequently, 97.5% of the respond-
ents would option for vaccination in the case that it is free. Authors con-
cluded that the social networks is the main stone in the campaigne focuses 
on the raising awareness of the need for HPV vaccination and cancer pre-
vention, including disseminating information to the target population. Ac-
cording to this and similar studies here in Serbia target population is still 
need more informations about HPV vaccination and the role of parents and 
health workers is crucial, as the vaccine is not mandatory, and parents’ ap-
proval is required but also the government of Serbia, have to make a great 
steps for health promotion and disease prevention. The governments of the 
European Union countries, as well as the government of Serbia, currently 
only spend a small part of the health budget for health promotion and dis-
ease prevention – around 3%. Will it be enough for all these very important 
pre-steps to spread an information before decision to implement HPV vac-
cination to buy it and to cover as much as it is possible of target population. 
We can not separate information and promotion programs and our wish to 
get coverage that will justify the cost-effectiveness of the vaccination pro-
gram. 
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Prevention of cervical cancer in Republic of N. 
Macedonia 
Goran Dimitrov 
Crude incidence rate of cervical cancer in the Republic of North Macedonia 
was 14.5. About 151 new cervical cancer cases are diagnosed annually in 
Macedonia (2018). Cervical cancer ranks as the 6th leading cause of female 
cancer in Macedonia. Cervical cancer is the 3rd most common female can-
cer in women aged 15 to 44 years in Macedonia. 
About 59 cervical cancer deaths occur annually in Macedonia (2018). Cervi-
cal cancer ranks as the 11th leading cause of female cancer deaths in Mace-
donia. Cervical cancer is the 5th leading cause of cancer deaths in women 
aged 15 to 44 years in Macedonia. [1] 
Based on the specified screening age range (24‐60 years), the population 
estimates for Macedonia in 2013 indicate the total eligible cervical screening 
population is ≈516,000 women. Therefore, using a 3-year screening interval, 
the total annual target population would be ≈172,000 women. [2] 
Cervical screening has also been funded by the government since 2006 when 
a program was established giving every women the right to voluntarily access 
free of charge screening through public hospitals. However, the initial cervi-
cal screening participation rates were low so this service was transferred to 
PHC (Primary Health Care) gynecologists in 2010, who were also given 
responsibility for sending letters of invitation to eligible women registered 
with the HIF (Health Insurance Fund) and assigned to their practices. Ap-
proximately 90% of Macedonian population is registered with the HIF so 
this system would ensure the majority of women aged 24-60 (the cervical 
screening age range) receive an invitation. However, no other elements of an 
organized cervical screening program have yet been implemented. [2] 
The type of screening test used in the Republic of N. Macedonia is not uni-
form: 80% of the testing is done with a conventional Pap smear, and 20% 
with liquid-based cytology. Cytotechnologists and cytopathologists at 12 
government based or private cytology laboratories use modified Bethesda 
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classification to evaluate cervical smears; however, there is no quality control 
monitoring program for cytology laboratories in the country. [3] The cover-
age of the target population of women has been relatively low (estimated on 
15–25%), since the beginning of the opportunistic screening in 1967 till 
nowadays (2018). The initial try for organized screening in 2012 was char-
acterized with a very low response rate to invitation letters (10-15%) and 
this correlates well with estimates that only 20,000 women were screened, 
compared to the “projected” total annual target of 172,000 women. [2] 
Although new updated screening Guidelines have been produced at the end 
of July, 2018 by an expert group formed by the Macedonian Society for 
Cervical Pathology and Colposcopy, Ministry of Health, Health Insurance 
Fund, UNFPA-Macedonia and other stakeholders there has not been any 
signs for its implementation. The emphasis was on HPV testing as primary 
screening tool. 
The use of HPV testing is still for triage of women with borderline or ab-
normal cytology results. Recommended and reimbursed indication for HPV 
testing in addition to borderline and low-grade cytology is also prediction of 
the outcome after treatment of CIN2+ (test of cure). HPV testing is per-
formed in government-based or private microbiology/virology laboratories, 
mostly by in-house PCR tests. 
Both the quadrivalent and bivalent vaccine have been registered in Republic 
of North Macedonia: the quadrivalent one since 2007, and the bivalent one 
since 2008. The official recommendations for the use of HPV vaccines were 
issued in 2007 by the Commission for Contagious Diseases within the Min-
istry of Health, the Macedonian Association of Gynecologists and Obstetri-
cians, the HPV Society of Macedonia, and the Macedonian Society for Cer-
vical Pathology and Colposcopy. Vaccination was recommended for females 
between 9 and 26 years old. By a decision of the Ministry of Health from 
2008, HPV vaccination was introduced into the national immunization 
program in October 2009 as obligatory for 12-year-old girls. The quadriva-
lent vaccine has been used in the national immunization program and is 
delivered through a school-based program. The catch-up vaccination (2009-
2011) was provided for 13 to 26-year old girls and women, and was free of 
charge and delivered through healthcare facilities. HPV vaccine coverage is 
monitored at the national level. Coverage for three doses increased from 
37% for the 2009/2010 school year to 67% for the 2010/2011 school year, 
and then declined to 65% for the 2011/2012 school year. [4] In the school 
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year 2014/2015, with the decision of the Ministry of Health according to a 
procurement act, a revert to the bivalent vaccine has been done. From that 
time till now the vaccination is with the bivalent HPV vaccine. In the school 
year 2015/2016 the coverage even for 2 doses (of the bivalent vaccine) 
dropped to less than 50%. From June 2018 there is a National recommen-
dation for gender neutral vaccination but still only girls are vaccinated with-
in the school Program. 
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Prevention of cervical cancer in Bosnia and 
Herzegovina 
Ermina Iljazović 
Abstract: : Bosnia and Herzegovina do not have a population-based registry 
of malignant disease. Crude incidence rate in B&H was from 23.07 in 2011 
to 29.14 in 2015 (per 100.000 women aged 15 and older). B&H has an 
opportunistic instead of organized screening, based on cytology (mostly 
conventional Pap test). According to the Strategy of the control, prevention 
and monitoring of malignant disease in FB&H for 2012-2020, a target 
population are woman aged 21 to 60 ys. The main aim is to reach women 
ages from 21 to 60 with recommended guidelines to reach 70% of recom-
mended screening. According to the data from the Retrospective Interna-
tional Survey and HPV Time Trends Study Group (UCC Tuzla lab was 
participated in the project) the incidence of HPV infection in the cervical 
cancer tissue was 55.17%, mostly present as single infection. All types of 
HPV vaccine are registered in B&H, but without any recommendation who 
should be vaccinated. 
Introduction: Bosnia and Herzegovina do not have a population-based reg-
istry of malignant disease and the number of new cases, of cervical cancer 
per year, varies depending on the size of the city or region. According to the 
recent study in East Europe, based mostly on the estimation from neigh-
bouring countries, crude incidence rate for Bosnia and Herzegovina is 26.6.  
According to the report of Public Health Institute in FB&H, incidence of 
cervical cancer is on the second place, just after breast cancer. In this study 
we presented preliminary data of approximate cervical cancer incidence in 
Bosnia and Herzegovina, collected during the period of 2011 till 2015. 
Crude incidence rate in B&H was from 23.07 in 2011 to 29.14 in 2015 
(per 100.000 women aged 15 and older). B&H has an opportunistic instead 
of organized screening, based on cytology (mostly conventional Pap test). 
According to the Strategy of the control, prevention and monitoring of ma-
lignant disease in FB&H for 2012-2020, a target population are woman 
 ___________________________     ___________________________  17 
aged 21 to 60 ys. The main aim is to reach women ages from 21 to 60 with 
recommended guidelines to reach 70% of recommended screening.  
Infection with one of the few oncogenic human papillomavirus (HPV) types 
is a necessary cause of invasive cervical cancer. HPV testing in Bosnia and 
Herzegovina started at 2000. in Tuzla University Clinical Center, and today 
is the most experience laboratory in this field and the greatest number of the 
performed tests (Qiagen HRHPV DNA II). There is not unique data inci-
dence for whole country yet, but most complete and most reliable data (12 
years data base) exist for the Tuzla region. According to the data from the 
Retrospective International Survey and HPV Time Trends Study Group 
(UCC Tuzla lab was participated in the project) the incidence of HPV in-
fection in the cervical cancer tissue was 55.17%, mostly present as single 
infection. The frequency of HPV infection among female in the same region 
is between 31.37% (2001.) and 59.25% (2003.) with more stable rate over 
the past 6 years (app 45%). The HPV incidence at Sarajevo region is also 
app 45%, with 47.7% in 2005. and 45.9% in 2011. 
All types of HPV vaccine are registered in B&H, but without any recom-
mendation who should be vaccinated. 
Conclusion: Presented data are of limited value due to lack of official last 
census data (2013) as well as lack of data base registry. Although of limited 
value, these data represent the more relevant results than the available data 
in the literature. 
All those facts underline the importance of the adoption of organized screen-
ing programme. One of the first steps of Bosnia and Herzegovina in the near 
future should be establishing of the registry of malignant disease, Pap test 
database and setting up well-organized cervical cancer prevention pro-
grammes as proposed by the European Council Recommendation. 
Key words: cervical cancer, HPV status, incidence, Bosnia and Herzegovina 
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National Cervical Cancer Screening Programme 
in Montenegro 
Đurđica Ostojić 
1 What is the incidence of cervical cancer in Montenegro? 
The first annual report of the Registry of Malignant Neoplasms of Monte-
negro presents the basic data on the morbidity and mortality from malig-
nant neoplasms in Montenegro for 2013. The most frequent malignant 
neoplasms sites in females were: 
• breast, 
• non-melanoma malignant skin neoplasms, 
• colon, rectum and anus, 
• trachea, lung and bronchus, 
• cervix uteri, and corpus uteri. 
Among young adults (20-34 years), the leading malignant neoplasms site in 
males was testicular neoplasm (42.4%), and neoplasms of breast and cervix 
uteri were the most frequent sites in females (25.8% each). In the age group 
35-49 years, most frequently reported sites in males were lung neoplasms 
(23.3%), and breast (36.6%) and cervix uteri (20.6%) neoplasms in females. 
According the first annual report of the Registry of Malignant Neoplasms of 
Montenegro, 106 women are diagnosed cervical cancer in 2013. With an 
age-standardized incidence rate (world standard WHO 2001) of 
27,6/100.000 Montenegro has one of the highest cervical cancer incidence 
rates in Europe. 
2 How is cervical cancer screening program organized? Does it 
fulfil criteria for the organised population-based programme?  
National cervical cancer screening program in Montenegro is being con-
ducted in accordance with the recommendations of the European Guide-
lines for Quality Assurance in Cervical Cancer Screening Second Edition 
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Supplements, EU 2015 and the Comprehensive Cervical Cancer Control: A 
guide to essential practice - 2nd edition, 2014. 
Legal framework for this programme and data management is in place.  
The target group for the National Cervical Cancer Screening Programme are 
women registered to chosen doctors for women- gynecologists in Primary 
Health Care Centres. The organized screening programme which includes 
screening test, additional diagnostics and treatment is free of charge for all 
participants. 
3 What are the age range of the target population and the 
frequency of screening?  
According to the National Programme for early detection of cervical cancer 
in Montenegro, target population age range is 30-64.The screening pilot 
project began on July 18, 2016 in municipality Podgorica. Target popula-
tion were women aged 30-34 years. Organised, population-based, nation-
wide screening programme was implemented on February 1, 2018. Target 
population were women aged 30-34 years, in Podgorica women aged 30-36 
and from February 1, 2019. target population are women aged 30-42 years. 
Programme is managed by Ministry of Health and Institute for Public 
Health of Montenegro, which collect data, monitor and evaluate each step 
of the programme. 
4 What test is used in the primary screening? Do we use liquid-
based technology?  
Screening is performed with HPV DNA test as a primary screening test 
within 18 Primary Health Care Centers in Montenegro. The screening cycle 
is five years. The accredited HPV testing laboratory is located at the Insti-
tute for Public Health of Montenegro. 
The Abbott RealTime hrHPV test detects the following genotypes: HPV16, 
HPV18 and hrHPV (31,33,35,39,45,51,52,56,58,59,66,68). The result of 
the test can be: positive (with some of the genotypes individually identified 
or combinations), negative, inadequate and negative that should be repeated 
after 12 months.  
HPV positive women are called for colposcopy and after three months liq-
uid-based cytology (LBC) testing. The period between HPV DNA testing 
and LBC sampling is three months because tests that are used for these tests 
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are from different manufacturers. Premature sampling of the PAPA test by 
the LBC method in less than three months period from the HPV testing 
might induce false negative results.  
The PAPA LBC method is examined by pathologists at the Pathology Clinic 
of Clinical Center of Montenegro.  
5 How is the invitation system organized? What is the coverage of 
the target population with invitations? What is the coverage of the 
target population with screening tests?  
Screening programme is conducted in Public health care system in Monte-
negro, organized in three levels: 
1. Primary health care level (18 Primary Health Care Centers in all mu-
nicipalities) 
2. Secondary health care level (General Hospitals in the seven largest cit-
ies)  
3. Tertiary health care level (Institute for Public Health and Clinical 
Centre of Montenegro in Podgorica). 
Screening programme is supported by electronic health information system 
(e-HIS) at all health care levels and for every step of the process. 
Teams of chosen gynecologists call women (from the group of target popu-
lation) by phone or SMS and schedule an appointment. If the woman does 
not respond, she is called two more times: after 3 and after 6 months. 
Screening participants fulfill two questionnaires. The first questionnaire 
aims to identify possible risk factors for cervical cancer, and the second ques-
tionnaire is eliminatory - with questions from personal and family history.  
In 2018, 10,677 women or 52.23% of the planned cohort were invited to 
participate in the program. A total of 7,038 (65.92%) women responded to 
the invitation to participate in the cervical cancer screening program, and 
6,634 (94.26%) were sampled for HPV testing (cervical swabs). 
6 How is HPV vaccination organised? What is vaccination 
coverage? Do we vaccinate girls and boys?  
Montenegro is in the process of implementation of HPV vaccination for 
girls. Start of the programme is planned for the end of the current year.  
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Cervical cancer prevention In Finland 
Pekka Nieminen 
Incidence in year 2017: 4,8 and mortality 1,0 (world standard) 
(www.cancer.fi) 
Organized nationwide screening from year 1963 
Also a lot of opportunistic screening 
Invitations are drawn from the population registry. Call-recall system. 
All 30-60 year old women are invited with 5 year interval, some municipali-
ties invite also 25 and 65 year old women. 
Target population: 1,3 million women 
Coverage of invitations is 98 %, attendance rate to organized screening is 72 
% 
Referral to colposcopy 1,1%, follow-up cytology recommended in 5,4% 
CIN 2+ cases 0,4% of screened women ( in programme) 
Over 90% of 20-65 year-old women have had at least one Pap-smear during 
the last 5 years (organized, opportunistic or both) 
A shift from the conventional Pap-smear to HrHPV-test in primary screen-
ing is going on in Finland. Year 2019 the Southern Finland implemented 
HPV-screening with cytology triage. No co-testing. 
Very little LBC is used in the screening. 
National HPV vaccination started in year 2013. Target group is 10-11 year-
old girls. School based vaccination. Coverage is 70%. The programme will 
be gender-neutral in year 2020, when boys will be included. Bi-valent con-
nive presently. 
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Prevention of cervical cancer in Slovenia 
Urška Ivanuš 
What is the incidence of cervical cancer in Slovenia? 
The population-level effects of organised population-based screening in 
Slovenia can already be observed with cervical cancer incidence reducing by 
half since the implementation of organised population-based cervical cancer 
screening programme ZORA in 2003 (Table 1). In the recent years, approx-
imately 120 women are diagnosed and 40‒50 women die in Slovenia every 
year because of cervical cancer. With an age-standardized incidence rate 
(world standard) of about 7/100.000 and mortality rate of about 2/100.000 
women, Slovenia is one of the European countries with the lowest cervical 
cancer burden. This is an outstanding achievement, since Slovenia used to 
have one of the highest cervical cancer incidence rates in Europe. 
In 2017, Slovenia observed a record low cervical cancer incidence with only 
85 new cases of cervical cancer (Table 1). This is undoubtedly a good news, 
but it should be interpreted with caution and re-evaluated in a year or two 
because of the small number of patients. Nevertheless, the decreasing trend 
in cervical cancer incidence in the recent years indicates Slovenia is, similarly 
to other countries with well-organised screening and vaccination pro-
grammes, following a path outlined in the spring of 2018 by the World 
Health Organization – the path to cervical cancer elimination. 
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Table 1. The incidence of cervical cancer since the implementation of pro-
gramme ZORA. Cervical cancer incidence data source is Cancer Registry of 
Slovenia, which is a dynamic database with possible changes in the number of 
new cases. Number of new cases is regularly updated in case of major changes via 
the website ZORA (https://zora.onko-i.si/). More information on cervical cancer and 
CIN3 up to 2016 can be found on the website SLORA (www.slora.si). 
YEAR 
Number of new 
cervical cancer 
cases (incidence) 
Number of new cervical cancer 
cases/100.000 women (crude 
incidence rate) 
Age-standardized incidence rate 
of cervical cancer/100.000 
women (world standard) 
2017 85 8,2 4,9 
2016 123 11,8 7,8 
2015 119 11,4 7,4 
2014 114 11,0 6,8 
2013 124 11,9 8,0 
2012 118 11,4 7,7 
2011 142 13,7 9,0 
2010 141 13,6 9,3 
2009 131 12,7 8,8 
2008 130 12,7 8,8 
2007 154 15,0 10,5 
2006 162 15,8 11,3 
2005 182 17,8 12,7 
2004 198 19,4 13,7 
2003 211 20,7 15,3 
How is cervical cancer screening program organized? Does it fulfil 
criteria for the organised population-based programme?  
Organised, population-based, nationwide screening programme ZORA was 
implemented in 2003. The organised screening process includes screening, 
diagnostics, treatment and follow-up after treatment (Figure 1). Programme 
is managed by the coordination office at the Institute of Oncology Ljublja-
na, which (in collaboration with the experts) provide guidelines, collect data, 
monitor and evaluate each step of the process. Target population are women 
aged 20–64 years. Screening is performed with conventional cytology within 
primary health care network of gynaecologists every 3 years. National evi-
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dence-based national guidelines are aligned with the European guidelines for 
women's management and laboratory procedures. Legal regulations exists 
for programme and data management (2 new regulations in 2018, aligned 
with GDPR). Centralised and personalised screening registry registers per-
sonalised data on women and is nightly synchronised with Central Popula-
tion Registry, it is also linked to Cancer registry of Republic of Slovenia. 
Copies of all cervical cytology results, HPV test results and all cervical histo-
pathology results including information about the hysterectomy from all 
women are sent to the central screening registry, regardless the reason for the 
test or procedure. Cytology and HPV data are standardised and received in 
electronic format, histopathology reports are not yet standardised and are 
received as a paper copy of the original report. Programme has public fund-
ing. 
What are the age range of the target population and the frequency 
of screening? 
Screening is performed with conventional cytology within primary health 
care network of gynaecologists every 3 years. 
What test is used in the primary screening? Do we use liquid-
based technology? 
Conventional cytology is used for screening since the introduction of the 
programme in 2003. Due to the good quality of smears (inadequacy rates 
are lower than 1%) there was no need to introduce liquid-based cytology in 
the past. However, according to new HPV-related knowledge and new 
technologies available, Slovenia is considering the introduction of HPV 
screening in women aged 35(30) years and more and in girls who were vac-
cinated against HPV within the national vaccination programme. The two 
of the first steps in the project of the renewal of the Slovenian cervical cancer 
screening policy are: (1) the introduction of liquid-based technology, that 
enables reflex testing with different tests (project started in 2019); (2) the 
renewal of the cervical cancer screening information system, that enables the 
real-time exchange of data between clinicians, laboratories and different 
national databases (including HPV vaccination registry) which will in the 
future enable risk-stratified screening, according to women’s age, HPV-
vaccination status and some other risk-factors (project started in 2017). 
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Figure 1. Clinical path of women in Slovenian cervical cancer screening pro-
gramme ZORA 
How is the invitation system organised? What is the coverage of 
the target population with invitations? What is the coverage of the 
target population with screening tests? 
Women have free access to their personal gynaecologists and do not need a 
special invitation to schedule a screening appointment. If a woman fails to 
make an appointment on time, her personal gynaecologist should invite her 
to make one (with a reminder if needed). The central cervical screening 
registry serves as a final supervisor of screening attendance. Women who not 
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had cytology result registered for four years, receive a central invitation, 
which is sent to her in the fifth year by the central coordination office at the 
Institute of Oncology Ljubljana. With the new information system that is 
under development, gynaecologists will have an option to choose to contin-
ue to use the current invitation protocol, or all the protocol where all the 
invitations will be sent from the central coordination office. 
Regular screening attendance is key for diagnosing precancerous and early 
cancerous lesions of the cervix. In the past five years, a little over 80% of 
women in the target population were screened in Slovenia, which places us 
amongst the most successful European countries. The recent three-year 
screening test coverage rate in Slovenia is over 70%, which is in line with 
our goals (Figure 2). The coverage rate in women aged 50 to 64 years has 
not reached our target values; however, in this age group coverage is slowly 
increasing (Figure 1). There are also differences in the coverage between the 
administrative units, three out of nine regions did not reach targeted 70% 
coverage in the last 3-year period (Figure 3).  
 
Figure 2. The three year coverage of the target population (%) by age in three 
three-year intervals (1 July 2009‒30 June 2012, 1 July 2012‒30 June 2015, 1 
July 2015‒30 June 2018). (Reference: Zora Registry, Institute of Oncology 
Ljubljana, January 2019, available at https://zora.onko-
i.si/publikacije/kazalniki). 
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Figure 3. The three year coverage of the target population in Slovenian regions 
in last three three-year interval (1 July 2015‒30 June 2018). (Reference: Zora 
Registry, Institute of Oncology Ljubljana, January 2019, available at 
https://zora.onko-i.si/publikacije/kazalniki). 
HPV test used in Slovenia and how is it used. 
HPV test was introduced in Slovenian cervical cancer screening programme 
ZORA in 2011 as a triage test and as test of cure after HSIL treatment. In-
dications for HPV triage are low grade cervical pathology (cytological con-
firmed ASC-US, cytological confirmed LISL≥35 years old or histologically 
confirmed LSIL) or histologically negative AGC-NOS. Hybrid Capture 2 
test (Qiagen, Germany) is used since the introduction of HPV test in 2011. 
According to the Regulation on cancer screening two laboratories in the 
country, can perform HPV testing. If HPV test will become a screening test 
in the future, we will strongly consider to select only one, clinically validated 
HPV test for all indications where HPV test will be used: screening of older 
women and HPV vaccinated, triage of younger women still screened with 
cytology and possibly also for HPV-self sampling of non-responders to regu-
lar screening. We are and we will strongly recommend against opportunistic 
use of HPV test outside the organised screening, especially in young women.  
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How is HPV vaccination organised? What is vaccination coverage? 
Do we vaccinate girls and boys? 
Slovenia has been vaccinating girls in the 6th grade of primary school against 
HPV free of charge since 2009, with the possibility of free vaccinations for 
order girls who missed their scheduled vaccination (catch-up vaccination). 
In last years, a 9-valent vaccine is used. According to the National Institute 
of Public Health (NIPH), the routine HPV vaccination coverage is around 
50%, which is too low. In 2019 NIPH proposed to include also boys at 6th 
grade in the national vaccination schedule, however this is not yet imple-
mented.  
Main messages on cervical cancer screening 
Cervical cancer is an exception amongst cancers, since we now have suffi-
cient knowledge and technology available to be able to prevent almost every 
new case. This is why in 2018, the World Health Organization issued a 
global call for action towards the elimination of cervical cancer as a public 
health problem with HPV vaccination, organised cervical cancer screening 
and treatment of cervical lesions with the cut-off level for elimination set at 
cervical cancer incidence rate (world standard) 4/100.000 women.  
The slow and gradual development of cervical cancer allows us to use differ-
ent ways of preventing cervical cancer with primary prevention measures 
(healthy lifestyle, HPV vaccination) as well as with secondary (early detec-
tion and treatment of precancerous and early cancerous cervical lesions in 
organised population-based screening programmes (Figure 4). Vaccination is 
very effective and safe and it is able to prevent 70-90% of all cervical cancers 
and high-grade precancerous lesions. Because vaccinated women can still 
develop disease from a HPV genotype not covered by the vaccine, vaccinat-
ed women should also attend screening.  
In order to achieve the optimal balance between harms and benefits of 
screening, only organised, population-based screening should be considered 
and implemented. Screening programmes should be organised according to 
Council recommendation on cancer screening (2003) and European guide-
lines for quality assurance in cervical cancer screening (2008 with extension 
about HPV testing and vaccination in 2015).  
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Figure 4. The prevalence of infection with at least one high risk HPV (green 
line, left axis) and the incidence of precancerous lesions HSIL/CIN3 and cervical 
cancer (blue and red line, right axis) in Slovenia, by age. The dashed line repre-
sents data extrapolated from foreign studies, since Slovenian data for these age 
groups do not exist. Reference: prevalence study of HPV infections in Slovenia 
(Učakar et al, Vaccine 2012) and website of Cancer registry of Slovenia – 
SLORA, for years 2005‒2009 (Institute of Oncology Ljubljana). 
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What can we learn from each other in our region? 
Suggestions for future activities 
Joško Zekan, Southeast European HPV Forum 
Abstract: During the transition period, most of the Southeast European 
countries experienced significant changes in the healthcare system, especially 
in the area of medical general practice. Privatization waves have significantly 
influenced health standards and the availability of health care. Part of the 
health care has been significantly improved. However, one part of health 
care has maintained the previous standards or there has been a weakening, 
especially in the case of diseases and conditions that have a public health 
significance. Among the world’s leading causes of morbidity and mortality, 
cervical cancer have understandably been the primary focus of research and 
development and the dominant motivation for international cooperative 
efforts at prevention and control. 
Objectives: Successfully organized, population-based cervical cancer screen-
ing programs have not yet been implemented in most southeast European 
countries, despite the greatest burden of cervical cancer. Effective perfor-
mance of the national program of organized screening in Slovenia started in 
2003. Incidence of cervical cancer decreased since then by 44%. However, 
from 2012 to 2016 the incidence of cervical cancer recorded the plateau. 
HPV vaccine coverage is about 50%. In Croatia, the organized cervical can-
cer screening started in 2012. Through 3 years of program, the incidence of 
disease was reduced by 18%. Since 2015, gender-neutral vaccination has 
been integrated into national immunization schedule and currently provides 
routine vaccination free of charge to the primary target population.  
Unfortunately, coverage by vaccination is less than 20% at the state level. In 
Bulgaria, Romania, Serbia, and Macedonia the implementation of organized 
cervical cancer prevention programs are in progress, current standard is op-
portunistic screening. Montenegro implemented organized HPV-based 
screening program In July 2016 (the only HPV-based program in the re-
gion). Also, there are no reliable data on HPV vaccination uptake. National-
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based screening solutions need to be found, while being cognizant of the 
criteria that have enabled successful screening programs. 
Conclusions: The reframed programs of cervical cancer prevention will in-
clude strategic combinations of at least two major components: extension and 
advancement of existing screening programs using HPV-based technology and 
routine introduction of HPV vaccines to both sex in all countries. Success in 
basic, clinical and epidemiological research has expanded the possibilities of 
cervical cancer prevention by introducing HPV-based cervical cancer screen-
ing and most importantly, by making available remarkably efficacious prophy-
lactic HPV vaccines. Understanding the nature of these tools, how to use 
them and how to evaluate their impact is a pressing social demand for the 
scientific, medical and public health communities. HPV vaccine uptake is 
reported, and support for conceptual models that move beyond purely moti-
vational accounts of HPV vaccine uptake is adduced. The Southeast European 
HPV Forum is a non-profit and non-governmental organization of southeast 
European countries with a goal to promote the research of all aspects of hu-
man papillomavirus (HPV) infection, to study diseases caused by HPV and 
help to implement and/or improve primary and secondary prevention pro-
grams of cervical cancer and other HPV-related tumors. 
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Cervical cancer 
Vitaly Smelov 
WHO recommends a comprehensive approach for cervical cancer preven-
tion and control that has 3 pillars: 
• Primary prevention, which consists mainly in HPV vaccination of 
girls 9-13 years. HPV vaccination does not fully abolish the need 
for cervical cancer screening in vaccinated cohorts as it does not 
prevent 100% of cervical cancers.  
• Secondary prevention, which consists in screening and for those 
found positive, follow-up and treatment. Cervical cancer screening 
should primarily be ensured for women aged 30-49.  
• Tertiary prevention, which ensures that women with invasive can-
cer have rapid access to diagnosis and effective treatment, as well as 
palliative care if needed.  
WHO guidelines on cervical cancer screening specify that: 
• HPV test, PAP smear and visual inspection with acetic acid (VIA) 
are all recommended screening tests, with a preference for HPV 
test. Pap test is not recommended if it is not already existing and 
functioning in the country. HPV test can be used alone or be fol-
lowed by a triage test  
• Cryotherapy, loop electrosurgical excision procedure (e.g. LLETZ 
or LEEP) and thermal ablation can provide effective and appropri-
ate treatment for the majority of women who screen positive for 
cervical pre-cancer; 
• Screening needs to be performed at least once in a lifetime for every 
woman aged 30-49. If resources allows, frequency of screening 
should be intensified, up to every 5 years if using HPV test and eve-
ry 3 years if using PAP smear. Shortening further screening intervals 
increase costs without bringing any substantial health benefit. 
• Screening should primarily be proposed to women aged 30-49. If 
high coverage is obtained and resources are available then older co-
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horts may be screened, up to 60 or 65 year of age. Screening with 
HPV test before age 30 is not recommended because of the high 
rate of false positives. Screening with cytology or VIA before 25 is 
not encouraged for the same reason.  
 
Screening does not only carry potential for benefit but also for harms (e.g. 
false negative/positive tests, too aggressive/suboptimal treatments of pre-
cancerous lesions, anxiety, (in)direct financial costs associated, etc).  
To secure the benefits of screening and minimize the harms, quality is the 
key. Low quality screening results in no benefit while harms were observed, 
which is unethical and has to be avoided at all cost. 
High quality screening requires: 
• Minimizing false positives and false negatives: those depend highly 
on performance of professionals running the tests. Professionals 
must be informed about their performances in order to be able to 
improve, keeping in mind that false positives and false negatives can 
never be totally avoided. 
• Rapid, efficient, safe and free-of-charge follow up for women 
screened positive: Follow-up is fully part of the screening program 
and has to be planned, given resources and implemented prior to 
launching the program. A referral system should also be implement-
ed. 
• High screening coverage of the target population: Population-based 
screening has to be preferred to opportunistic screening. 
• Equity: special efforts need to be made to screen “hard to reach” 
women (e.g. poor/rural population). 
• Information systems: monitoring of process and outcome are crucial 
for attaining and for maintaining quality, and for guiding further 
improvement.  
